QuidelOrtho Corp (QDEL) Form 8-K — Nov 3, 2026
QuidelOrtho reported Q3 2026 revenue of $619 million, down 12% year over year, with a GAAP net loss of $54 million and adjusted diluted EPS of $0.31. The decline was driven by China IVD pricing changes, a soft respiratory season (-39% respiratory revenue), and the collapse of U.S. Donor Screening (-96%). The company launched a cost transformation and enterprise restructuring program expected to deliver over $80 million in annual savings in 2027, with $30-$35 million in one-time charges in Q4 2026.
Key figures
- Revenue
- 618900000
- Guidance
- FY2026 revenue $2.52-$2.54B (narrowed from $2.52-$2.60B); adjusted EBITDA $540-$545M; adjusted diluted EPS $0.65-$0.70 (narrowed from $0.65-$0.90)
- Cash Position
- 166400000
- Adjusted eps
- 0.31
- Labs revenue
- 353200000
- Adjusted ebitda
- 148000000
- Executive base salary
- 650000
- Point of care revenue
- 119600000
- Adjusted ebitda margin
- 23.9%
- Equity award value each
- 2000000
- Immunohematology revenue
- 142000000
- Executive retention bonus
- 650000
- Annual savings target 2027
- over $80 million
- Restructuring charges q4 2026
- $30-$35 million
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.